These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35284786)

  • 1. Predictive value of FibroScan in detecting liver fibrosis in HBeAg negative patients with chronic hepatitis B whose HBV DNA 2000-20000 IU/ml with ALT 1-2 times the upper limit of normal and those with HBV DNA >20000 IU/ml and normal ALT.
    Danis N; Salih Akarca U; Turan I; Karasu Z; Ersoz G; Yilmaz F; Nart D; Zeytinoglu A; Selda Erensoy M; Gunsar F
    North Clin Istanb; 2021; 8(6):568-574. PubMed ID: 35284786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of FibroScan in liver fibrosis evaluation in patients with chronic hepatitis B virus infection and related influencing factors].
    Xie QX; Xu N; Jiang XP; Zhang YF; Zhang ZH; Li JB; Hu XY; Li X
    Zhonghua Gan Zang Bing Za Zhi; 2016 Sep; 24(9):659-664. PubMed ID: 27788721
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors for advanced liver fibrosis in chronic hepatitis B virus infection with persistently normal or mildly elevated alanine aminotransferase.
    Wang D; Zhang P; Zhang M
    Exp Ther Med; 2017 Dec; 14(6):5363-5370. PubMed ID: 29285064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases.
    Oliveri F; Coco B; Ciccorossi P; Colombatto P; Romagnoli V; Cherubini B; Bonino F; Brunetto MR
    World J Gastroenterol; 2008 Oct; 14(40):6154-62. PubMed ID: 18985805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.
    Duan M; Chi X; Xiao H; Liu X; Zhuang H
    Hepatol Int; 2021 Apr; 15(2):318-327. PubMed ID: 33638049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical value of noninvasive method in diagnosing hepatic fibrosis about chronic HBV carriers].
    Zhang XY; Qian J; Li P; Hu LH; Mi YQ
    Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):332-336. PubMed ID: 29996199
    [No Abstract]   [Full Text] [Related]  

  • 10. HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication.
    Praneenararat S; Chamroonkul N; Sripongpun P; Kanngurn S; Jarumanokul R; Piratvisuth T
    BMC Gastroenterol; 2014 Dec; 14():218. PubMed ID: 25523185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers.
    Assy N; Beniashvili Z; Djibre A; Nasser G; Grosovski M; Nseir W
    World J Gastroenterol; 2009 Jun; 15(24):3025-31. PubMed ID: 19554656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis.
    Sonneveld MJ; Brouwer WP; Hansen BE; Chan HL; Piratvisuth T; Jia JD; Zeuzem S; Chien RN; Choi H; de Knegt RJ; Wat C; Pavlovic V; Gaggar A; Xie Q; Buti M; de Man RA; Janssen HLA;
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1399-1406. PubMed ID: 32886813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
    Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alanine aminotransferase course, serum hepatitis B virus DNA, and liver stiffness measurement for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B.
    Charatcharoenwitthaya P; Phisalprapa P; Pausawasdi N; Rungkaew P; Kajornvuthidej S; Bandidniyamanon W; Chotiyaputta W; Chainuvati S; Tanwandee T
    Hepatol Res; 2016 Dec; 46(13):1347-1357. PubMed ID: 26946348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B.
    Seto WK; Wong DK; Fung J; Ip PP; Yuen JC; Hung IF; Lai CL; Yuen MF
    PLoS One; 2012; 7(8):e43087. PubMed ID: 22916211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B.
    Xie Q; Hu X; Zhang Y; Jiang X; Li X; Li J
    J Med Virol; 2014 Nov; 86(11):1828-37. PubMed ID: 25145769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B.
    Sanai FM; Helmy A; Bzeizi KI; Babatin MA; Al-Qahtani A; Al-Ashgar HA; Al-Mdani AS; Al-Akwaa A; Almutharea S; Khan MQ; Alghamdi AS; Farah T; Al-Hamoudi W; Saadeh M; Abdo AA
    J Viral Hepat; 2011 Jul; 18(7):e217-25. PubMed ID: 21692936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in basal core promoter is associated with significant fibrosis in both HBeAg positive and negative treatment-naïve chronic hepatitis B.
    Yan LB; Zhu X; Bai L; Tang XQ; Du LY; Chen EQ; Liang LB; Tang H
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):296-302. PubMed ID: 27988305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristic of liver pathology in HBeAg-positive and HBeAg-negative chronic hepatitis B patients with mildly elevated ALT].
    Liu SQ; Zhu XJ; Sun XH; Li M; Gao YQ
    Zhonghua Gan Zang Bing Za Zhi; 2012 May; 20(5):348-52. PubMed ID: 22971279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLINICAL PHASES OF CHRONIC HEPATITIS B AMONG GEORGIAN PATIENTS.
    Zakalashvili M; Butsashvili M; Zarkua J; Abzianidze T; Kamkamidze G; Metreveli D
    Georgian Med News; 2022 Jan; (322):26-29. PubMed ID: 35134754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.